Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
about
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse modelPoxvirus vectors as HIV/AIDS vaccines in humansA global approach to HIV-1 vaccine developmentA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays.A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.The influence of delivery vectors on HIV vaccine efficacySystems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysModified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathwayPercutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesExtent of Systemic Spread Determines CD8+ T Cell Immunodominance for Laboratory Strains, Smallpox Vaccines, and Zoonotic Isolates of Vaccinia Virus.Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine StrategySequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military PopulationsA vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.Enhancing poxvirus vectors vaccine immunogenicity.A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsOptimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies.Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.Clinical applications of attenuated MVA poxvirus strain.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Developments in Viral Vector-Based Vaccines.Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Microneedle-mediated delivery of viral vectored vaccines.A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Maternal plasma and breastmilk viral loads are associated with HIV-1-specific cellular immune responses among HIV-1-exposed, uninfected infants in Kenya.Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice.Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization.Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.SIV-Specific Antibodies are Elicited by a Recombinant Fowlpox Virus Co-expressing SIV Gag and envTPotent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
P2860
Q24276422-55576D65-C193-4372-9911-4751969ECE41Q26995078-4EB79B6D-F5E8-404D-8842-1AD08C6888FBQ27024614-56C6BE11-DE8B-4EE8-A789-6043824F9F0CQ27302081-96C6798C-D177-44EC-98DA-51FEBE060D81Q30364312-EF960C87-4BA9-4729-8471-CA905141ECADQ30426851-CCD0EB45-ADD6-4D41-B4C5-03FA95464332Q30934059-42DB74C0-EF0D-45DE-8D38-10794CEBC2F0Q34077543-DDFDA880-8A8C-4C9D-8BFE-455EFBDF5B20Q34247289-251E3841-C520-42DF-84DC-F822849DA665Q34465228-E7AFDDA5-9386-453E-85C1-C950220F303FQ34729962-321186A0-C785-4901-BCEE-3D5ACE70616FQ34796206-1099BAF2-5C0E-4486-9EB9-ED48A8D5D163Q35151746-D3C5DA30-1BAC-4D17-B2C0-302F77027F57Q35928588-776665CE-4904-408E-8D86-09C75EB428BBQ35988486-571AA5DA-942D-4E5F-A532-A7A4E5DBC9C8Q36002028-EE0DB61D-05EF-447D-88C1-51E1D43B8456Q36119504-6AA1045A-87C3-4040-B55A-184753A8366DQ36238314-7187894E-8B8C-4A7D-9625-25056CE084EEQ36391900-F9663716-848C-4A36-BD32-68B0F69CEFEBQ36668517-10AB7B45-E597-4E9A-99C9-5E91563DC110Q36978452-2D1C5838-82EF-40AF-8705-9F929D5FD7DAQ37004283-C02B5E5C-AACB-4987-94BE-A74342A900A3Q37218080-13E61450-9BBE-4C73-A777-41C2E65168DFQ37512215-4E6C82ED-8E1B-43A5-A7EC-847A86587469Q37615969-AF680ECE-3AB8-424F-AD13-7C6859610F5CQ37643731-B536144C-6DE5-4B16-89F9-78E98166083FQ38156198-9E67C02E-05B9-4348-BC95-3701613303F8Q38415577-3ABF42C5-62E9-4C65-AB61-21FC008C6615Q38582090-EB10C06F-6B81-4C0C-A4F4-7993B227AAB1Q40091488-D44F9B7A-A992-4E32-B549-B4DF799A714EQ40220988-B1461294-7D88-463F-86B9-460C0E181B4BQ40596089-8FC65115-3C46-44A3-8B9A-FDA1E72CA487Q40919787-7F51037A-B74F-4AB2-8955-58DB4D077617Q41478363-1BE88D92-DFE2-46A8-8B2D-6D9E454DBEEAQ42217775-475F8504-6957-4D4B-A9E5-938530C40653Q42411962-ADE2C093-F852-4049-8800-8CB94A959C98Q44569389-C8E73B42-5BEE-4A8F-A9DB-F4DE5E5887D5Q47375908-8228EA32-0990-430F-B57A-579CAF31A6C9Q56556108-0C0A9067-DB8F-418A-ADE8-56F0F9BA75EDQ57009763-4F30D2B9-0B3C-41E9-B679-0E90D23ED82E
P2860
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety and immunogenicity of a ...... e I clinical trial (RISVAC02).
@en
type
label
Safety and immunogenicity of a ...... e I clinical trial (RISVAC02).
@en
prefLabel
Safety and immunogenicity of a ...... e I clinical trial (RISVAC02).
@en
P2093
P50
P1433
P1476
Safety and immunogenicity of a ...... se I clinical trial (RISVAC02)
@en
P2093
Agathe León
Alberto C Guardo
Amparo Alvarez
Beatriz Perdiguero
Carmen E Gómez
Iñaki Pérez
Joan Albert Arnaiz
Jonathan Weber
Jose L Nájera
José Luis Jiménez
P304
P356
10.1016/J.VACCINE.2011.08.098
P407
P50
P577
2011-09-09T00:00:00Z